XImmune Overview

  • Year Founded
  • 2009

Year Founded

  • Status
  • Out of Business

  • Latest Deal Type
  • Out of Business

XImmune General Information

Description

Developer of a drug research center designed to turn natural immunity into drugs. The company's drug research center utilize endogenous peptides as novel modulators to develop a peptide-based anti-inflammatory treatment for sepsis, enabling patients to consume necessary drugs without any side effects.

Contact Information

Website
www.ximmune.com
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • LU Innovation System
  • Box 117
  • 221 00 Lund
  • Sweden
+46 076-828
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Vertical(s)
Corporate Office
  • LU Innovation System
  • Box 117
  • 221 00 Lund
  • Sweden
+46 076-828

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

XImmune Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Out of Business 01-Oct-2015 Completed Out of Business
3. Buyout/LBO (Secondary) 01-May-2014 Completed Startup
2. Secondary Transaction - Private 01-Jan-2009 $1.36M Completed Startup
1. Early Stage VC 01-Jan-2009 $1.36M $1.36M Completed Startup
To view XImmune’s complete valuation and funding history, request access »

XImmune Patents

XImmune Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-2500184-A Polypeptide derived from helix a of heparin cofactor ii Inactive 12-Mar-2012
GB-201204283-D0 Polypeptides and uses thereof Inactive 12-Mar-2012
AU-2010299630-A1 Heparin cofactor ii fragments with anti-inflammatory and anti-coagulant activity Inactive 22-Sep-2009
AU-2010299630-A2 Heparin cofactor ii fragments with anti-inflammatory and anti-coagulant activity Inactive 22-Sep-2009
CA-2774288-A1 Heparin cofactor ii fragments with anti-inflammatory and anti-coagulant activity Inactive 22-Sep-2009 C07K14/8121
To view XImmune’s complete patent history, request access »

XImmune FAQs

  • When was XImmune founded?

    XImmune was founded in 2009.

  • Where is XImmune headquartered?

    XImmune is headquartered in Lund, Sweden.

  • What industry is XImmune in?

    XImmune’s primary industry is Drug Discovery.

  • Is XImmune a private or public company?

    XImmune is a Private company.

  • What is XImmune’s current revenue?

    The current revenue for XImmune is .

  • How much funding has XImmune raised over time?

    XImmune has raised $1.36M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process